Le Lézard
Classified in: Covid-19 virus
Subjects: Photo/Multimedia, Product/Service

Fera Pharmaceuticals Announces the Launch of Dexamethasone 4 mg Tablets USP in Unit Dose Packaging


Fera is pleased to announce that, in addition to its already marketed 100-count bottle package size, it has now launched a 100-count unit dose blister package as well. The advantages of unit dose packaging include improved safety for hospital staff and patients and to help minimize inaccurate dosing.

Fera believes the availability of this product will be important to hospital staff and their patients especially in light of the recent preliminary finding that in patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those receiving either ventilation or oxygen1.

About Fera Pharmaceuticals

Fera Pharmaceuticals is a privately held company. The company goal is to realize opportunities via acquisitions, in-licensing, developing and marketing abbreviated new drug applications (ANDAs), new drug applications (NDAs) and 505(b)(2) NDA products. For more information visit www.ferapharma.com.

References

  1. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19?Preliminary Report. NEJM. July 17, 2020.

FRA-1


These press releases may also interest you

at 21:00
SETC-Assistance.org Helps Eligible Self-Employed Workers Receive Up to $32,220 in Tax Credits Through SETC Program
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

at 19:30
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - QDEL
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

at 19:05
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

at 18:51
Bladex announces 1Q24 Net Profit of $51.3 Million, or $1.40 per share, expanding its annualized return on equity to 16.8% in 1Q24
Banco Latinoamericano de Comercio Exterior, S.A. , a Panama-based multinational bank originally established by the central banks of 23 Latin-American and Caribbean countries to promote foreign trade and economic integration in the Region, announced...

at 17:20
NOVAGOLD Releases 2023 Sustainability Report
Providing a comprehensive overview of NOVAGOLD's Environmental, Social and Governance (ESG) performance, emphasizing remarkable health and safety records, steadfast dedication to environmental protection, continuous community investment, extensive...

at 16:45
Dogness Reports Financial Results for the Six Months Ended December 31, 2023
Dogness (International) Corporation ("Dogness" or the "Company") , a developer and manufacturer of a comprehensive line of Dogness-branded, OEM and private label pet products, today announced its financial results for the six months ended December...

More news about Covid-19 virus...


News published on and distributed by: